标题：血清可溶性ST2在心力衰竭中的研究进展

      作者：李明瑞 综述 钟志雄 审校    广东医科大学，广东 湛江 524000

      卷次： 2022年33卷15期

      【摘要】 心力衰竭是大多数心血管疾病发展的终末阶段，也是共同结局，其高患病率、高死亡率、预后差对患者的生命健康造成极大威胁。因此，寻找特异性的血清生物标志物用于心衰的诊断、治疗及预后评估具有重要意义。ST2是近年来心血管方面的研究热点之一。与目前常用心衰标志物脑钠肽(BNP)相比，ST2稳定性更高，受年龄、肾功能和肥胖等因素影响小，被认为是心衰的潜在生物标志物。本文从ST2的生物学特征、抗炎抗纤维化机制以及在心衰诊断、治疗和预后等方面的进展进行综述，评估其作为心衰生物标志物的应用价值。
      【关键词】 心力衰竭；可溶性ST2；白介素33；生物标志物；临床应用
      【中图分类号】 R541.6 【文献标识码】 A 【文章编号】 1003—6350（2022）15—2004—04

Advances in the research of serum soluble ST2 in heart failure.
LI Ming-rui, ZHONG Zhi-xiong. Guangdong MedicalUniversity, Zhanjiang 524000, Guangdong, CHINA【Abstract】 Heart failure is the end stage and common outcome of most cardiovascular diseases. With the highprevalence, high mortality and poor prognosis, heart failure poses a great threat to the life and health of patients. There-fore, it is important to identify specific serum biomarkers for the diagnosis, treatment and prognosis assessment of heartfailure. ST2 is one of the hot spots in cardiovascular research in recent years. Compared with the currently used heart fail-ure marker brain natriuretic peptide (BNP), ST2 is more stable and less affected by age, renal function and obesity, andthus is considered as a potential biomarker for heart failure. In this paper, we review the biological characteristics, anti-in-flammatory and anti-fibrotic mechanisms of ST2 and its progress in the diagnosis, treatment and prognosis of heart fail-ure, and evaluate its application value as a biomarker of heart failure.
      【Key words】 Heart failure; Soluble ST2; Interleukin-33; Biomarker; Clinical application　　　·综述·doi:10.3969/j.issn.1003-6350.2022.15.027基金项目：广东省自然科学基金(编号：2020A1515010430)